Hot Investor Mandate: Family Office Associated Investment Firm Seeks Early-Stage Medical Device and Diagnostic Technologies, as well as Therapeutics

2 Jan

An investment firm located in the USA and associate with a family office registered in the Cayman Islands is managing a $100MM fund, the firm invests in angel and seed stage, and its typical allocation size is between $200,000 to $750,000. The firm invests in companies based in the United States, especially in the Silicon Valley area, and normally invests four to five companies every year.

The firm is interested in diagnostics and medical devices in general, especially cancer diagnostics. Regarding therapeutics, it is open to the data platforms for therapeutics and orphan diseases.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI San Francisco 2020 Innovation Challenge Finalists Selected

19 Dec

By Claire Jeong, Director of Research, Asia BD, LSN

claire

We’re excited to announce the RESI San Francisco Innovation Challenge finalist companies (just in time for the holidays!). With RESI San Francisco being our most popular event, over 150 innovative companies across therapeutics, devices, diagnostics, and digital health applied to participate.

For those of you who are not familiar with the Innovation Challenge, this is a competition we organize at every RESI conference. Finalists will bring a posterboard showcasing their company and technology, which will be presented at a dedicated exhibition hall for the entire day. All attendees will be provided with “RESI Cash”, which they can use to “invest” in their favorite, most innovative companies. The Top 3 winners with the most RESI Cash will be announced during our cocktail reception.

Whether you will be attending RESI San Francisco or not, we highly recommend that you check out these companies through their clickable logos and see what they have to offer. Best of luck to the participating companies, and we look forward to seeing all of the incredible technologies next month on January 14th!

Therapeutics

Medical Devices

 

Diagnostics

Digital Health

Announcing the Featured Company Pitch Sessions – Watch These Startups Present at RESI San Francisco 2020

19 Dec

By Karen Deyo, Senior Investor Research Analyst, LSN

For RESI San Francisco, LSN introduced the new Featured Company Pitch Session, an opportunity for companies to register to pitch at RESI San Francisco. There was an overwhelming response, with over 150 applications for the limited spots available. The morning sessions are focused on companies in therapeutics, medical devices and advanced platforms and tools, plus a session sponsored by Dayli Partners featuring their most innovative portfolio companies. In the afternoon, Global Family Office Bioforum will lead three focused sessions on Alzheimer’s Diagnosis & Treatments, Cancer Diagnostics, and Women CEOs.  All these sessions will take place in RESI’s theatre on the 2nd floor of Marines’ Memorial Club & Hotel.  Make sure to block off time on your schedule at RESI San Francisco to see these companies pitch!

8:00AM – 9:00AM
BIOTECH ENTREPRENEUR PITCH SESSION
9:00AM -10:00AM
MEDTECH ENTREPRENEUR PITCH SESSION
10:00AM – 11:00AM
ADVANCED PLATFORMS & TOOLS PITCH SESSION
11:00AM – 12:00AM
KOREA ENTREPRENEUR PITCH SESSION
SPONSORED BY 
1:00PM – 2:00PM
ALZHEIMER’S DIAGNOSIS & TREATMENT PITCH SESSION
SPONSORED BY 
2:00PM – 3:00PM
WOMEN CEOs PITCH SESSION
SPONSORED BY 

 

3:00PM – 4:00PM
CANCER DIAGNOSTICS PITCH SESSION
SPONSORED BY 

How Do You Measure Your Partnering Meeting Success?

19 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

It’s challenging to raise an early stage financing round.  You need to build strong marketing collateral, and only then launch an outbound financing campaign. And then, you face the challenge of how to measure the effectiveness of the myriad partnering events you might attend during your campaign.  How does a scientist-entrepreneur gauge how a meeting went and what are the metrics they should use?  When running a fundraising campaign executives need to be vigilant in ranking which meetings were successful and may lead to further dialogue.  One learning milestone for all fundraising CEOs is being diligent about which players stay on the list and which ones are removed because of lack of interest or lack of fit.

LSN’s RESI Conference Series offers attendees a partnering system with a built in “matching algorithm” that will parse all the investors and recommend with which investors the companies should try and connect. The algorithm is based on the investor’s criteria in terms of product, stage of development, and other key parameters.  When a company gives a pitch at RESI Conference to an investor audience or meets an investor in a one-on-one meeting, they are pitching to potential partners that are a fit for them.  Typically at other partnering venues, up to half of the thirty minute meeting is trying to determine “who is selling who” and what the person on the other side of the table is seeking.  RESI Partnering has eliminated that downside.

Many conferences have partnering as a “me too” segment, as opposed to RESI, which is a dedicated partnering conference; all the partners at RESI have been screened for fit and vetted to ensure they are active investors with current investment mandates in order to comply with RESI’s investor pass program.  Another distinct feature when you attend a RESI conference is that investors can also be identified by the red ribbons on their badges!

Here are some important metrics to consider:

Fit. This is the most important metric in meetings.  Did a company meet a potential partner that was a fit for their stage of development and product?

Did the investor want to have a follow-up meeting?

-Did they express interest in signing an NDA?

-Did they refer you to other peers, colleagues or investors?

-Did they take the time to engage you at other times during the networking activities and receptions?

These metrics are what determines  “success” at a partnering event.  By using the information gathered by LSN’s Investor Research team fundraising executive and investors are more efficient and as a result have much more compelling meetings. With the possibility of booking up to 16 meetings at each RESI event, a scientist-entrepreneur attending RESI’s regular US and international events can connect with investors that are a good fit on a global level.  As fundraising is a numbers game, good meetings that are a fit  are the key to your company’s success.

Hot Investor Mandate: Venture Fund Invests US-Wide in 510k Devices

19 Dec

A venture firm based in California makes early stage investments ranging from $100k – $3M, occasionally making larger investments outside of this range.  The firm is flexible in terms of structure with both equity and convertible notes being used. The group will fund, incubate and help develop new technologies at the earliest stages (ideas with no IP) as well as invest in established venture stage companies. The firm will both lead rounds as well as invest with a syndicate. The firm is focused on companies and technologies based in the USA or having their primary business in the USA.

The firm is primarily focused on the medtech and device space, and will evaluate diagnostic technologies that have a device component (tests/IVDS, etc. are not considered). The group is fairly opportunistic, however has specific interests in orthopedics, dermatology, neurovascular, endovascular, women’s health, ophthalmology and general surgical devices and products. The firm is only interested in technologies with a 510(k) regulatory pathway. The group will invest in devices/products in development or at the clinical stage.

The firm has no stricture company or management requirements and is open to working with all entrepreneurs. The company may seek a board seat long with investment, but it is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Worldwide Asset Management Firm Invests in Life Sciences With a China Angle

19 Dec

The proprietary venture capital and private equity arm of a worldwide asset management organization has a fund focused on venture investments related to Greater China.  With an evergreen fund structure, the firm can be flexible in terms of investment sizes (up to $250 million per deal) and horizon. The firm typically makes equity investments. The fund invests in businesses based in China or with a China angle. The firm’s management team also collaborates closely with its parent company’s other funds on international deals.

Within life sciences, the fund works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The fund is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: European VC Invests in Medtech, Diagnostics and Digital Health

19 Dec

A European focused venture capital firm founded in 2015 with partners based in Europe and US is currently actively investing in Spain, Portugal, the UK, and Ireland. The firm is expanding into the Baltics and raising a new €100 million fund. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in series A & series B financings as a Lead or co-Lead with investments ranging from €3 million to €8 million over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over next 4 years. The firm will only invest in private companies.

The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is strongly interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platform and analytics areas, such as big data-driven technologies on complex medical research.

The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: